| Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, and Interest Expense and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales, depreciation and amortization, operating profit, and interest expense for the three and nine months ended August 31, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
For the three months ended August 31, |
|
|
|
2023 |
|
|
2022 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
7,862,949 |
|
|
$ |
7,522,134 |
|
PrepaCyte CB |
|
|
2,543 |
|
|
|
21,000 |
|
Public cord blood banking |
|
|
4,383 |
|
|
|
137,825 |
|
Total net revenue |
|
$ |
7,869,875 |
|
|
$ |
7,680,959 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,976,278 |
|
|
$ |
1,883,400 |
|
PrepaCyte CB |
|
|
982 |
|
|
|
10,622 |
|
Public cord blood banking |
|
|
178,927 |
|
|
|
454,733 |
|
Total cost of sales |
|
$ |
2,156,187 |
|
|
$ |
2,348,755 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,341,332 |
|
|
$ |
1,268,146 |
|
PrepaCyte CB |
|
|
(5,384 |
) |
|
|
3,433 |
|
Public cord blood banking |
|
|
(174,904 |
) |
|
|
(317,268 |
) |
Total operating profit |
|
$ |
1,161,044 |
|
|
$ |
954,311 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
273,972 |
|
|
$ |
274,598 |
|
PrepaCyte CB |
|
|
6,945 |
|
|
|
6,945 |
|
Public cord blood banking |
|
|
360 |
|
|
|
360 |
|
Total depreciation and amortization |
|
$ |
281,277 |
|
|
$ |
281,903 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
469,642 |
|
|
$ |
365,349 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
469,642 |
|
|
$ |
365,349 |
|
|
|
|
|
|
|
|
|
|
For the nine months ended August 31, |
|
|
|
2023 |
|
|
2022 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
23,006,164 |
|
|
$ |
22,159,702 |
|
PrepaCyte CB |
|
|
61,920 |
|
|
|
75,600 |
|
Public cord blood banking |
|
|
398,896 |
|
|
|
337,405 |
|
Total net revenue |
|
$ |
23,466,980 |
|
|
$ |
22,572,707 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
5,466,410 |
|
|
$ |
5,343,455 |
|
PrepaCyte CB |
|
|
27,432 |
|
|
|
63,934 |
|
Public cord blood banking |
|
|
872,895 |
|
|
|
1,246,108 |
|
Total cost of sales |
|
$ |
6,366,737 |
|
|
$ |
6,653,497 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
4,333,538 |
|
|
$ |
4,538,058 |
|
PrepaCyte CB |
|
|
13,654 |
|
|
|
(9,168 |
) |
Public cord blood banking |
|
|
(475,079 |
) |
|
|
(909,783 |
) |
Total operating profit |
|
$ |
3,872,113 |
|
|
$ |
3,619,107 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
821,287 |
|
|
$ |
818,081 |
|
PrepaCyte CB |
|
|
20,834 |
|
|
|
20,834 |
|
Public cord blood banking |
|
|
1,080 |
|
|
|
1,080 |
|
Total depreciation and amortization |
|
$ |
843,201 |
|
|
$ |
839,995 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,405,825 |
|
|
$ |
947,968 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
1,405,825 |
|
|
$ |
947,968 |
|
The following table shows the assets by segment as of August 31, 2023 and November 30, 2022:
|
|
|
|
|
|
|
|
|
|
|
As of |
|
|
As of |
|
|
|
August 31, 2023 |
|
|
November 30, 2022 |
|
Assets: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell
service |
|
$ |
60,226,085 |
|
|
$ |
54,849,697 |
|
PrepaCyte CB |
|
|
150,869 |
|
|
|
176,546 |
|
Public cord blood banking |
|
|
9,419,412 |
|
|
|
9,861,811 |
|
Total assets |
|
$ |
69,796,366 |
|
|
$ |
64,888,054 |
|
|